Higher plasma 25 (OH)D levels linked to lower mortality in colorectal cancer

Harris, Jason; Shafer, Emily
July 2008
Hem/Onc Today;7/25/2008, Vol. 9 Issue 13, p27
The article discusses research being done on the link between plasma 25 (OH)D levels and mortality risk in patients with colorectal cancer. It references a study published in the 2008 issue of the "Journal of Clinical Oncology." The study included 304 patients diagnosed with colorectal adenocarcinoma in the U.S. Study researchers found that patients with higher plasma 25 (OH)D levels have reduced mortality risks.


Related Articles

  • Colon cancer in Luxembourg: a national population-based data report, 1988-1998. Scheiden, René; Pescatore, Paul; Wagener, Yolande; Kieffer, Nelly; Capesius, Catherine // BMC Cancer;2005, Vol. 5, p52 

    Background: Over the last two decades time trends in incidence rates of colorectal cancer, changes in the proportions of stage at diagnosis and changes in the anatomic sub-site distribution of colon cancers have been reported in some European countries. In order to determine a strategy for early...

  • Characteristics of patients dying within 30 days of diagnosis of breast or colorectal cancer in Scotland, 2003-2007. Brewster, D. H.; Clark, D. I.; Stockton, D. L.; Munro, A. J.; Steele, R. J. C. // British Journal of Cancer;1/4/2011, Vol. 104 Issue 1, p60 

    Background:Recent research has shown that most of the excess risk of death following breast and colorectal cancer in England compared with Norway and Sweden occurs in older age groups during the first year, and especially in the first month of follow-up. The aim of this study was to explore the...

  • Targeting metastatic colorectal cancer - present and emerging treatment options. Ciombor, Kristen K.; Berlin, Jordan // Pharmacogenomics & Personalized Medicine;2014, Vol. 7, p137 

    Metastatic colorectal cancer is a significant cause of morbidity and mortality in the US and around the world. While several novel cytotoxic and biologic therapies have been developed and proven efficacious in the past two decades, their optimal use in terms of patient selection, drug...

  • Expression profiling based on graph-clustering approach to determine colon cancer pathway. Xiao-qu Zhu; Mei-lan Hu; Feng Zhang; Yu Tao; Chun-ming Wu; Shang-zhu Lin; Fu-le He // Journal of Cancer Research & Therapeutics;Jul-Sep2013, Vol. 9 Issue 3, p467 

    Context: Colorectal cancer is the second leading cause of cancer deaths worldwide. DNA microarray-based technologies allow simultaneous analysis of expression of thousands of genes. Aim: To search for important molecular markers and pathways that hold great promise for further treatment of...

  • The Increasing Incidence of Colorectal Cancers Diagnosed in Subjects Under Age 50 Among Races: CRaCking the Conundrum. Carethers, John; Carethers, John M // Digestive Diseases & Sciences;Oct2016, Vol. 61 Issue 10, p2767 

    No abstract available.

  • Outcome Of Patients With Acute Intestinal Obstruction Due To Colorectal Carcinoma. Rasool, Alataf; Bari, Shams-ul; Rashid, Shafaq; Wani, Asif Hamid; Wani, Rouf Ahmad; Peer, Ghulam Qadir // Internet Journal of Surgery;2009, Vol. 20 Issue 1, p23 

    Background: Understanding of the biology of colorectal cancer and improvement in surgical techniques have led to significant improvements in the management of colorectal cancers and reduction of morbidity associated with it. Aim and Objective: Aim of the study was to know the effect of various...

  • Targeted therapies in colorectal cancer: surgical considerations. Luu, Carrie; Arrington, Amanda K.; Schoellhammer, Hans F.; Singh, Gagandeep; Kim, Joseph // Journal of Gastrointestinal Oncology;Sep2013, Vol. 4 Issue 3, p328 

    Colorectal cancer (CRC) is a leading worldwide health concern that is responsible for thousands of deaths each year. The primary source of mortality for patients with CRC is the development and subsequent progression of metastatic disease. The most common site for distant metastatic disease is...

  • What if cancer survival in Britain were the same as in Europe: how many deaths are avoidable? Abdel-Rahman, M.; Stockton, D.; Rachet, B.; Hakulinen, T.; Coleman, M. P. // British Journal of Cancer;12/3/2009 Supplement 2, Vol. 101, pS115 

    Objective:To estimate the number of deaths among cancer patients diagnosed in Great Britain that would be avoidable within 5 years of diagnosis if the mean (or highest) survival in Europe for patients diagnosed during 1985–1989, 1990–1994 and 1995–1999 were...

  • Cancer survival in England and the influence of early diagnosis: what can we learn from recent EUROCARE results? Thomson, C. S.; Forman, D. // British Journal of Cancer;12/3/2009 Supplement 2, Vol. 101, pS102 

    Background:This review of the EUROCARE-4 results attempts to separate out the early and late mortality effects contributing to the widely reported poorer 5-year survival rates for cancer patients in the United Kingdom compared with other European countries for 26 cancer sites.Methods:Patients...

  • Post-diagnostic oral bisphosphonate use and colorectal cancer mortality: a population-based cohort study within the UK Clinical Practice Research Datalink. Hicks, B M; Murray, L J; Hughes, C; Cardwell, C R // British Journal of Cancer;6/30/2015, Vol. 113 Issue 1, p123 

    Background:We conducted the first study to investigate post-diagnostic oral bisphosphonates use and colorectal cancer-specific mortality.Methods:Colorectal cancer patients were identified from the National Cancer Data Repository (1998-2007) and linked to the UK Clinical Practice Research...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics